

**Supplementary Figure S3: Recurrence-free survival is significantly associated with tuberculin-induced IL-2 secretion prior to induction therapy.**  Kaplan-Meyer survival plots show recurrence-free survival. **(A)** Survival of all individuals over the follow-up period. Censored events are shown as filled circles. **(B)** By retrospectively assigning individuals to two groups based on a cut-off of 250pg/ml of tuberculin-induced IL-2, two significantly different survival curves are generated, illustrating the potential of tuberculin-induced IL-2 secretion in predicting BCG immunotherapy outcome. The dotted vertical lines indicate the 6 months time point.